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Abstract 
The humoral immune response to Epstein-Barr virus (EBV) in classic Hodgkin lymphoma (cHL) 
stratified by EBV tumor status is unclear.  We examined IgG and IgA antibody responses against 202 
protein sequences representing 86 EBV proteins using a microarray and sera from 139 EBV-positive cHL 
cases, 70 EBV-negative cHL cases, and 141 population-based controls frequency matched to EBV-
positive cHL cases on sex and age by area (UK, Denmark, and Sweden).  We leveraged existing data on 
the proportion of circulating B-cells infected by EBV and levels of serum CCL17, a chemokine secreted 
by cHL tumor cells, from a subset of the cHL cases in the UK.  Total IgG but not IgA response level was 
significantly different between EBV-positive cHL cases and controls.  The distinct serological response 
included significant elevations in 16 IgG antibodies and 2 IgA antibodies, with odds ratios highest vs. lowest 
tertile >3 observed for the following EBV proteins:  LMP1 (oncogene), BcLF1 (VCAp160, two variants), 
and BBLF1 (two variants).  Our cHL IgG signature correlated with the proportion of circulating EBV-
infected B-cells, but not serum CCL17 levels.  We observed no differences in the anti-EBV antibody 
profile between EBV-negative cHL cases and controls.  BdRF1(VCAp40)-IgG and BZLF1(Zta)-IgG were 
identified as the serological markers best able to distinguish EBV-positive from EBV-negative cHL 
tumors.  Our results support the hypothesis that differences in the EBV antibody profile are specific to 
patients with EBV-positive cHL and are not universally observed as part of a systematically dysregulated 
immune response present in all cHL cases.   
Novelty and Impact 
Our data expand beyond the limited number of anti-EBV IgG antibodies evaluated in classic Hodgkin 
lymphoma (cHL) patients to date and provide evidence of a systemic difference in the EBV antibody 
profile in cHL cases that is both specific to EBV-positive tumors and includes immune aberrations 
reflecting exposure to multiple stages of the viral life cycle.  Evidence of increased, systemic exposure to 
EBV lytic-cycle activity supports a role for ongoing viral activity in tumor pathogenesis. 
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Introduction 
Epstein-Barr virus (EBV), a gamma-herpesvirus that infects lymphoid and epithelial cells and 
establishes lifelong latency in 90% of adults globally, is associated with a range of human diseases, 
including classic Hodgkin lymphoma (cHL) 1, 2.  It is estimated that EBV is causally related to 20%-50% 
of cHL tumors in immunocompetent people, with the virus being localized to the malignant Hodgkin 
Reed-Sternberg (HRS) cells 3, 4.  Serologic data provide further evidence to support the association 
between EBV infection and cHL.  Reports evaluating anti-EBV antibodies against the viral capsid antigen 
[VCA], early antigen [EA], Epstein-Barr nuclear antigen 1 [EBNA1] and EBNA2, and latent membrane 
protein 1 [LMP1]) indicate that cHL patients harbor elevated levels of anti-EBV IgG antibodies 5-13.  
However, most investigations to date have analyzed responses to complexes of proteins (e.g. VCA), 
rather than individual peptides, and have not investigated reactivity against the full complement of 
approximately 100 open reading frames translated by EBV.  Whether antibodies against sequences 
representing additional EBV antigens can provide new etiologic insights into the nature of the association 
between EBV and cHL is unknown.   
The EBV status of cHL tumors must be considered when characterizing the immune response to 
EBV in relation to cHL.  Epidemiological data and molecular characteristics suggest that EBV-positive 
and EBV-negative cHL are likely to be etiologically distinct diseases 4, 8, 9, 14-16.  However, not all of the 
serological studies conducted to date have distinguished between EBV-positive and EBV-negative tumors 
in their analyses 5-7, 10.  Indeed, many cHL-related studies are limited by a lack of knowledge of tumor 
EBV status 8, 9, largely because limited availability of tumor tissue precludes EBV testing and stratified 
analyses.  A serological tool would obviate the need for tumor tissue to conduct work accounting for cHL 
EBV status and could therefore prove very useful in future epidemiological research.   
To address these gaps in knowledge, we applied a recently developed protein microarray 
technology to measure both IgG and IgA antibody responses against a comprehensive set of sequences 
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representing 86 EBV proteins in 350 individuals from previous cHL case-control studies conducted in 
European populations.  
Materials and Methods 
Study design 
Serum samples were selected from studies of cHL in the UK 17, 18, Denmark, and Sweden 19.  
Briefly, samples from the UK were derived from two population-based case-control studies and three case 
series (a total of 102 EBV-positive cases, 41 EBV-negative cases, and 106 controls) between 1993 and 
1997 17, 18.  Samples from Denmark and Sweden were collected as part of the Scandinavian Lymphoma 
Etiology (SCALE) study, a population-based case-control study conducted among adults in Denmark and 
Sweden between 1999 and 2002 (37 EBV-positive cHL, 37 EBV-negative cHL, and 37 controls) 19.  All 
study subjects were non-Hispanic Caucasians.  We excluded eight EBV-negative cases and two controls 
without high quality serum for EBV protein microarray testing, leaving a total of 139 EBV-positive cases, 
70 EBV-negative cases, and 141 controls in the present study.  Tumor EBV status was determined using 
immunohistochemical staining of tumor biopsies for EBV latent membrane antigen (LMP)-1 and/or in 
situ hybridization for EBV-encoded small RNAs (EBERs).  All cases were cHL and samples were 
collected prior to cancer treatment.  Samples from controls were frequency matched to EBV-positive cHL 
cases on sex and age (± 5 years) by study area, and the EBV-positive and EBV-negative cHL cases were 
further matched on clinical stage.  The EBV-negative case group was included to determine whether 
differences in the EBV antibody pattern were specific to EBV-positive tumors.   
All contributing studies were approved by regional scientific ethics committees and data 
protection agencies, and all participants provided informed consent. 
EBV protein microarray  
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 We probed serum samples using an EBV protein microarray targeting IgG and IgA antibodies 
against 202 EBV sequences including three synthetic peptides 20 and 199 predicted EBV protein 
sequences representing non-redundant open reading frames in 86 EBV proteins from five prototypical 
EBV strains (AG876, Akata, B95-8, Mutu, and Raji), as previously described 21-25.   Details are presented 
in Supplementary Materials.  Comparison with the outputs from a well-established enzyme-linked 
immunosorbent assay (ELISA) showed high correlations between the microarray IgA output and 
previously generated ELISA data for IgA antibodies against VCAp18 and EBNA1 (Spearman coefficient 
= 0.76 and 0.79, respectively; P < 0.01).25   Each sequence, including the EBV life cycle of each probe 
based on updated mechanistic information from the literature, is provided in Table S1.   
We included 25 blinded duplicate samples for quality control during testing and observed good 
reproducibility (i.e., coefficient of variation [CV]<20%) for antibodies measured using this custom 
protein microarray.  The average CV across the 202 EBV sequences was 12.5% (interquartile range 
[IQR]: 11.3-14.0 %) for IgG and 14.5% (IQR: 13.1-16.1%) for IgA.  We excluded one IgG and five IgA 
array spots that had CVs >20% from the analysis, leaving a total of 201 IgG and 197 IgA markers.   
Circulating B-cells infected with EBV and CCL17 chemokine levels 
It is plausible that an elevated antibody response in cHL patients could be attributable to long-
standing, uncontrolled EBV activity that pre-disposes to disease, or to increased exposure to viral antigens 
resulting from the presence of the tumor. To begin disentangling these two possibilities, we leveraged 
existing data from a subset of the cHL cases diagnosed in the UK on two metrics – the proportion of 
circulating B-cells infected by EBV (N=14 EBV-positive cases), and levels of the chemokine CCL17 
(thymus and activation-regulated chemokine TARC; N=47 EBV-positive cases).  
To determine the frequency of circulating EBV-infected B-cells, peripheral blood mononuclear 
cells (PBMCs) were isolated from peripheral blood (50 – 60 ml) using Lymphoprep™ (Axis-Shield, 
Dundee, UK), and then B-cells enriched using a CD20+ MiniMACS Separation system (Miltenyi Biotec 
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Ltd, Surrey, UK). Serial √10-fold (3.16-fold) dilution of the enriched B-cells was performed, and eleven 
replicates of each dilution, containing 3.16 × 104 to 3.16 × 102 cells, were subjected to real-time PCR. If 
insufficient cell numbers were available for the complete dilution series, the starting cell number was 
reduced, as appropriate. Ten replicates of each dilution were assayed for EBV using a previously 
described PCR targeting the EBV BamHI W repeat sequence, and the final replicate was assayed for β-
globin gene to check that amplifiable DNA was present 26.  PCRs contained 50 nmol/l of each primer, 200 
nmol/l of probe, TaqMan Universal PCR Mastermix (ThermoFisher Scientific, Paisley, UK), and the cell 
lysate in a total volume of 25 µl. PCR and analysis were performed on an Applied Biosystems 7500 Fast 
Real-Time PCR System using software v2.0.6 (ThermoFisher Scientific).  Each of the EBV PCRs in the 
dilution series was scored as positive or negative, and results analysed using ELDA software 26.  Results 
are expressed as the estimated number (and 95% confidence interval [CI]) of EBV-positive cells per 106 
B-cells.  DNA from the Namalwa cell line was used as a positive control, and nine no template controls 
were included in each assay. 
CCL17 was quantified using a Human CCL17/TARC Quantikine ELISA (R&D Systems®, 
Abingdon, UK), according to the manufacturer’s instructions 26.  Pre-treatment serum samples were 
initially tested at a 1 in 10 dilution, and further dilutions were analyzed when results fell outside the 
dynamic range of the assay.  All samples were analyzed in duplicate and results used only if coefficients 
of variance (CVs) were <20%; mean values are reported. 
Statistical analysis 
To examine the association between biological groupings of antibody response (e.g., responses 
directed against lytic-cycle proteins) and cHL, we used the SNP-set (Sequence) Kernel Association Test 
(SKAT) 27 with a binary variable parameterization for each marker (1=positive, 0=negative).  Effect 
estimates for biological groupings of antibody response were considered statistically significant if their P-
value was ≤ 0.005, corresponding to a Bonferroni correction for 10 tests (10 different stages of the viral 
life cycle evaluated).   
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We investigated differences in the mean standardized signal intensity (SSI) for IgG and IgA 
antibodies against each of the 202 array sequences across EBV-positive cHL cases, EBV-negative cHL 
cases, and controls using one-way analysis of variance (ANOVA).  We computed p-values for all two-
way comparisons between groups (e.g., EBV-positive cHL versus controls).  Our original hypothesis was 
that case-control differences would be limited to EBV-positive cHL.  Antibody associations with cHL 
were considered statistically significant if their P-value was ≤ 1.3 × 10-4, corresponding to a Bonferroni 
correction for 400 tests (about 200 probes on IgG antibodies and IgA antibodies).  
Odds ratios (ORs) and 95% CIs for the association between each 3-level categorical anti-EBV 
antibody variable (i.e., tertiles) and cHL status were calculated using polytomous logistic regression 
models adjusted for sex, age, and study area.  Among subjects from the SCALE study for whom 
information on a history of infectious mononucleosis (IM) was complete (information on IM was missing 
for 52% of the subjects in the UK), models were further adjusted for a history of IM.  P-trends were 
calculated from a model with each 3-level antibody marker treated as an ordinal variable using Wald test.  
Because the etiology may differ between young-adult cHL and older-adult cHL28-30 and the age-specific 
incidence decreases from age 20 to 40 years but increases after age 40 years 30, we assessed heterogeneity 
of associations by age group (<40 years vs. ≥40 years).  A likelihood ratio test was used to compare 
logistic regression models with and without an interaction term between each anti-EBV antibody and age 
group.  We also evaluated cHL in relation to the anti-EBNA1/anti-EBNA2 ratio (≤1 vs. >1), a metric that 
has been used in previous serological studies as a proxy for defective immunity against EBV 31, 32.   
In addition to comparing anti-EBV humoral immunity between cHL cases and controls, we also 
conducted additional analyses to understand which set of markers was best able to distinguish EBV-
positive from EBV-negative cHL.  Specifically, we first computed the MeanDecreaseGini and 
MeanDecreaseAccuracy metrics using random forests (R package randomForest,).  Second, we evaluated 
antibodies with differences meeting the P ≤ 1.3 × 10-4 threshold using a stepwise logistic regression 
model as both continuous and categorical variables (tertiles). We set P < 0.15 as the model entry criterion 
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and P < 0.05 for an antibody to remain in the model (LOGISTIC procedure in the SAS statistical 
package).  Finally, we selected markers that were selected by both the stepwise logistic regression and the 
two randomForest prediction metrics as our best potential predictors.  We evaluated the ability of the 
selected anti-EBV antibody markers (as continuous levels) together with the subject’s characteristics (i.e., 
age group, sex, and study area) to classify the EBV status of cHL tumors using the area under the receiver 
operative curve (AUC).  We compared this AUC with that obtained based only on the subject’s 
characteristics with a 10-fold cross-validation.  
The datasets generated during and/or analysed during the current study are available from the 
corresponding author on reasonable request. 
Results 
Table 1 shows the distribution of baseline demographic characteristics among the 139 EBV-
positive cHL cases, 70 EBV-negative cHL cases, and 141 controls.  Cases and controls had a similar age 
and sex distribution.  As expected, nearly all adults in this population were EBV carriers, as illustrated 
using two of the synthetic peptides on the array.  Among controls, EBV-negative cHL cases, and EBV-
positive cHL cases, the sero-positive rates for IgG antibodies against VCAp18 were 92.9%, 88.6%, and 
98.6%, respectively; for IgG antibodies against EBNA1, rates were 87.9%, 85.7%, and 84.2%, 
respectively.   
Among cHL samples from the UK where information on the histopathology was available, 47 
cHL cases were mixed cellularity, and 73 were nodular sclerosis subtype.  We observed no significant 
differences in SSI between 40 EBV-positive cases with mixed cellularity and 46 with nodular sclerosis 
(all Bonferroni-corrected P values from t-test >0.05). 
EBV-positive cHL cases vs. controls  
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The proteome-wide IgG repertoire (i.e., a combination of the IgG antibody responses to all array 
probes) was statistically significantly different between EBV-positive cHL cases and controls (PSKAT-C for 
total IgG=0.003, PSKAT-C for total IgA=0.128, Figure 1A).  When considering anti-EBV antibody 
responses against proteins from specific stages of the EBV life cycle, the EBV-directed IgG repertoire to 
late lytic (PSKAT-C = 0.001) and early lytic (PSKAT-C =0.004) proteins differed significantly between EBV-
positive cHL cases and controls (Figure 1A).  We also observed a suggestive association for the IgG 
repertoire against sequences representing latent proteins (PSKAT-C =0.020). 
 Comparison of the mean difference in SSI for each individual array sequence between EBV-
positive cHL cases and controls revealed nominally significant differences (P≤0.05) in 56.7% of the IgG 
(114/201) and 4.6% of the IgA (9/197) anti-EBV antibodies.  Sixteen IgG and two IgA anti-EBV 
antibodies remained significantly elevated in EBV-positive cHL cases after adjusting for multiple testing 
(Pt-test ≤ 1.3×10-4; Figure 1B and Table 2).   The most pronounced SSI differences between EBV-positive 
cHL cases and controls were observed for IgG antibodies against sequences representing three lytic-cycle 
enzymatic proteins (BBRF1, Thymidine Kinase [TK] and BBLF1) and one component of the viral capsid 
(BcLF1) (Figure S1A-1D).  We also observed strong IgA differences between EBV-positive cases and 
controls for two probes on the array representing BBLF1.   
After adjustment for age, sex, and residential area, ORs highest vs. lowest tertile for antibodies with Pt-test ≤ 
1.3×10-4 ranged from 1.79 to 4.99 (Table 2), and IgG markers representing three EBV proteins (BcLF1, 
BBLF1, and LMP1) had adjusted ORs > 3.  The strongest OR effect was observed for antibody against 
sequences representing LMP-1 (adjusted OR highest vs. lowest tertile=4.99, 95% CI: 2.51, 9.94, Ptrend<0.0001), an 
EBV oncogene that is highly expressed by the HRS cells in EBV-positive cHL 33.  The mean array output 
(SSI level) representing IgG responses to these three proteins in EBV-cHL cases ranged from 1.09 for 
LMP1 to 2.21 for BBLF1, levels comparable to the IgG response in these cases to known disease 
biomarkers VCA-p18 and EBNA1 (2.00 and 1.62, respectively).  No heterogeneity in the EBV-cHL 
11 
associations was observed by age group (<40 years vs. ≥40 years, all Pheterogeneity >0.05 after Bonferroni 
correction).  
EBV-positive cHL cases were more likely than controls to have an aberrant EBNA response 
pattern (i.e., anti-EBNA1:EBNA2 ratio <1), although most associations were not statistically significant 
after considering all possible combinations of the various EBNA1 and 2 probes on the array (Table S2).  
Among participants from the SCALE study, additional adjustment for a history of infectious 
mononucleosis did not materially change the observed associations (Table S3).   
Correlation of IgG markers with the proportion of EBV-infected B-cell or chemokine CCL17 levels  
To investigate potential underlying mechanisms driving the elevated anti-EBV IgG signature in 
EBV-positive cHL patients, we examined the correlations between our top markers and either (1) the 
proportion of circulating B-cells infected by EBV or (2) levels of the chemokine CC17, an indirect 
measure of tumor burden, using Spearman correlation coefficients.  Of the 18 antibodies (16 IgG and 2 
IgA) that associated with EBV-positive cHL, suggestive correlations (P-values<0.05) were observed 
between three markers (i.e., BBRF1-IgG, BBLF1-IgG, and BcLF1-IgG) and the proportion of EBV-
infected B-cells in circulation, with the highest Spearman coefficient observed for BBRF1-IgG 
(Spearman coefficient=0.588, P-value=0.027, Figure S2A).  By contrast, none of the 18 antibodies were 
correlated with chemokine CCL17 levels, as illustrated in Figure S2B for BBRF1-IgG.  
EBV-negative cHL cases vs. controls  
 Neither the IgG nor IgA proteome-wide repertoire was significantly different between EBV-
negative cHL cases and controls (Figure 2A). No specific IgG or IgA anti-EBV antibodies were 
significantly different in EBV-negative cHL cases compared to controls after adjusting for multiple 
testing (Figure 2B).   
EBV-positive cHL cases vs. EBV-negative cHL cases 
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 EBV-positive cHL patients were more likely than EBV-negative cHL patients to display an 
elevated anti-EBV IgG response (Figure 3A).  A total of six IgG markers met the P ≤ 1.3×10-4 
significance threshold for elevation specific to EBV-positive cHL (Table 3).  Adjusted ORs highest vs. lowest 
tertile for these six antibodies ranged from 2.94 to 5.27 (Table 3).  We further assessed which of these 
markers were best able to distinguish EBV-positive from EBV-negative cHL based on random forests and 
stepwise logistic regression prediction metrics (BZLF1[Zta]-IgG and BdRF1[VCAp40]-IgG, Figures 
S3A-3B).  The prediction performance for classifying EBV-positive versus EBV-negative cHL was 
significantly improved by including these two antibodies (continuous variable, area under the curve 
[AUC]=0.75, 95% CI=0.68, 0.83) versus considering only subject age, sex, and study area alone 
(AUC=0.64, 95% CI=0.56, 0.72, P-value=0.002, Figure 3B).  Based on a 10-fold cross-validation, the 
AUC of this combination of serological markers plus patient demographics was 0.70 (95% CI: 0.63, 
0.78).  
Discussion 
 This is the first study to evaluate the antibody response to the complete EBV proteome in cHL 
patients.  Our results demonstrate that EBV-positive cHL cases have distinct serological responses 
compared with both EBV-negative cHL cases and controls.  The significant elevations in 16 IgG and two 
IgA markers in EBV-positive cHL cases are unlikely to be confounded by age, sex, and residential area.  
Notably, no difference in the anti-EBV antibody profile was observed between EBV-negative cHL cases 
and controls.  Our results support the hypothesis that differences in the EBV antibody profile are specific 
to patients with EBV-positive cHL and are not universally observed as part of a systematically 
dysregulated immune response present in all cHL cases. 
The EBV-positive cHL disease associations were disproportionately observed for IgG rather than 
IgA markers.  This finding stands in contrast to the elevated levels of IgA antibody,  which marks 
exposure to antigens along mucosal surfaces such as the oral epithelium,11 that we and others report in 
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patients with nasopharyngeal carcinoma (NPC), an EBV-associated epithelial tumor.11, 25  Previous 
studies have reported significant elevations in IgA antibodies against VCA and EA among patients with 
EBV-positive cHL,6, 8 and we observed a difference between EBV-positive cHL and controls for BBLF1-
IgA.  However, the lack of a broad IgA response specific to EBV-positive cHL cases supports the 
hypothesis that IgG antibodies indicative of systemic exposure to EBV infection of circulating B-cells 
constitute a more relevant marker for lymphoid tumors.  Results from a similar study among pediatric 
patients with Burkitt lymphoma (BL) also support the absence of a strong disease effect for IgA in 
lymphoid tumors 34.   
Historically, studies largely focused on antibodies against sequences representing four EBV 
protein complexes or antigens: VCA, EA, EBNA1, and EBNA2.  Here, we extend these findings to 
include antibodies against a broad panel of viral proteins involved in various stages of the EBV life cycle.  
Notably, we observed strong associations for immune responses representing EBV proteins involved in 
replication, including the early (TK, BBLF1, and BALF2 [EA(D)_p138]) and late lytic cycle (several 
components of viral capsid [BcLF1 and BdRF1] and BBRF1) antigens.  We could not determine in this 
retrospective study design whether this lytic activity was due to the presence of neoplastic tissue, or 
whether it is reflecting an ability to control EBV in the years preceding cHL diagnosis. A prospective 
study could potentially elucidate whether individuals exhibit the unique anti-EBV antibody pattern prior 
to disease onset, but such a study design is challenging due to the low incidence of cHL.  
To begin to understand the biology underlying the EBV-positive cHL antibody signature, we 
leveraged existing data relevant to two alternative hypotheses that the elevated anti-EBV IgG responses 
reflect a history of uncontrolled EBV infection that predisposes to disease, or that this antibody signature 
is a reflection of EBV antigen production in the tumor.  Although our data are not definitive, our cHL IgG 
signature correlated with the proportion of EBV-infected circulating B-cells, rather than CCL17 level (an 
indirect indication of tumor burden) 35. This supports the assertion that the ability to control EBV 
replication prior to disease is associated with cHL risk, as suggested previously 36.  
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In addition to elevated lytic-cycle EBV activity in cHL, we observed significant associations 
between EBV-positive cHL and IgG antibody responses to LMP-1, BHRF1, and BARF1, three proteins 
that are implicated in oncogenesis 33, 37, 38.  These antibodies do not necessarily directly reflect EBV gene 
expression in the tumor, but elevated expression of these molecules may be relevant for B-cell survival 
and eventual risk of tumor development 12, 13.  LMP-1 functions as a constitutively active CD40 molecule 
leading to NF-kappaB signaling and up-regulation of pro-apoptotic proteins including Bmi-1 (Bcl-2-
interacting mediator of cell death) 37.  In EBV-associated cHL, it is thought to play a key role in rescuing 
HRS cells, or their precursors, from apoptotic death in germinal centers.  BHRF1 is an EBV homolog of 
Bcl-2, and BARF1 also has anti-apoptotic function 39, suggesting that these proteins may also contribute 
to cell survival at some stage in disease pathogenesis. Despite eliciting a weaker overall immune response 
than some traditional disease biomarkers (e.g., VCA), reactivity to LMP-1 was significantly higher in 
EBV-positive cHL patients relative to disease-free controls.  
Importantly, our present findings support the body of epidemiological evidence suggesting that 
EBV-positive and EBV-negative cHL are distinct diseases 4, 8, 9, 14-16 .  Chang et al. reported that EBV-
positive tumors were more likely than EBV-negative tumors to affect adults with less education and a 
history of cigarette smoking.8  In addition, people with a history of infectious mononucleosis, which is 
caused by primary EBV infection in adolescence or young adulthood, are at a higher risk of developing 
EBV-positive cHL but not EBV-negative cHL.14, 15, 40, 41  Despite this evidence supporting two distinct 
diseases, a lack of cHL tumor tissue samples for EBV status testing often precludes researchers from 
conducting risk factor analyses stratified by EBV status.  A serological tool that could distinguish EBV 
status could therefore be immensely useful.  Classic serological markers (e.g., EBNA1-IgG) did not yield 
a significant discrimination between EBV-positive and EBV-negative cHL cases in our study, which is in 
line with previous findings 11, 12.  Examining the antibody profile against the full viral proteome allowed 
us to identify a two-marker combination that classified tumor EBV status in our samples better than 
patient demographics alone: BdRF1(VCAp40)-IgG and BZLF1(Zta)-IgG.  Whether these two markers 
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can achieve high accuracy for distinguishing EBV-positive from EBV-negative cHL using only blood 
samples merits further investigation.  Such a blood-based tool for determining tumor EBV status would 
represent an opportunity to utilize large and racially diverse biobanks for cHL research without 
necessitating the presence of archived tumor for EBER staining.   
Our results should be interpreted in light of certain methodologic limitations.  First, although 
there is strong biologic plausibility for the association between antibody responses to EBV and EBV-
positive cHL, our observations of case-control differences for specific markers need independent 
validation.  In addition to identifying case-control differences in the EBV-directed antibody repertoire, 
our case-case comparison identified a two-marker combination that classified tumor EBV status among 
cases.  Although this two-marker combination was internally validated using 10-fold cross-sampling in 
our study population, our approach is still considered as exploratory since we lacked an independent, 
external dataset for replication.  Second, we lacked information for all subjects on education level, 
smoking, a history of infectious mononucleosis (IM), and other potential confounding factors.  However, 
although IM is a risk factor for EBV-positive cHL, the prevalence of this disease in our study population 
overall appeared to be relatively low (i.e., ~9% among 108 subjects from the SCALE study).  Among 
subjects for whom information on a history of IM was available, additional adjustment for IM did not 
materially change the observed antibody associations.  Likewise, in a previous study, adjustment for 
potential confounding factors did not appreciably change the associations between anti-EBV antibodies 
(i.e., VCA, EA, EBNA1, and EBNA2) and EBV-positive cHL.8  Another limitation to note was that this 
array was not designed to detect antibodies to conformational epitopes, which precluded us from 
examining cHL associations for select transcripts that require glycosylation, including surface 
glycoproteins involved in virus neutralization.   
In conclusion, we characterized EBV-directed antibody responses to 202 protein sequences 
representing 86 EBV proteins in cHL patients.  Compared with patients with EBV-negative cHL and 
controls, patients with EBV-positive cHL displayed a distinct EBV-directed serological profile, with 
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significant elevation in several IgG antibodies.  This disease-associated antibody pattern included 
differences in antibody responses to proteins involved in EBV replication and anti-apoptotic signaling, 
providing clues for future EBV-positive cHL pathogenesis research.  Future studies are needed to better 
understand why some individuals cannot control EBV infection appropriately and how antibody 
responses reflect this process and can be used for risk stratification.  Additional studies to elucidate 
etiological factors for EBV-negative cHL are also needed, as the etiology of this subset of cHL remains 
elusive. 
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Table 1. Baseline characteristics by case-control status a 
Characteristics 
EBV-positive cHL 
cases 
(n=139) 
EBV-negative cHL 
cases 
(n=70) 
Controls 
(n=141) 
Study Area 
   
  Scotland, UK 102 (73.4) 36 (51.4) 104 (73.8) 
  Demark 15 (10.8) 15 (21.4) 15 (10.6) 
  Sweden 22 (15.8) 19 (27.1) 22 (15.6) 
Sex 
   
  Female 45 (32.4) 25 (35.7) 45 (31.9) 
  Male 94 (67.6) 45 (64.3) 96 (68.1) 
Age at diagnosis (years) b 
  
  <30 41 (29.5) 22 (31.4) 44 (31.2) 
  30 - 39 24 (17.4) 18 (25.7) 25 (17.7) 
  40 - 49 17 (12.3) 6 (8.6) 17 (12.1) 
  50 - 59 27 (19.6) 10 (14.3) 29 (20.6) 
  60+ 29 (21.0) 14 (20.0) 26 (18.4) 
Histological subtype    
  Mixed cellularity 40 (28.8) 7 (10.0) -- 
  Nodular sclerosis 46 (33.1) 27 (38.6) -- 
  Other/Unknown c 53 (38.1) 36 (51.4) -- 
Clinical Stage 
   
   I 18 (20.0) 9 (12.8) -- 
   II 40 (43.5) 34 (48.6) -- 
   III 19 (20.6) 16 (22.9) -- 
   IV 15 (13.9) 11 (15.7) -- 
   Unknown 47 0 -- 
Abbreviation: cHL, classic Hodgkin lymphoma  
a All data are given as n (%) except where indicated 
b Age information was missing for one EBV-positive cHL case  
c Other includes lymphocyte-depleted, lymphocyte-rich classic, and unclassified types. 
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Table 2. Odds ratios (OR) and 95% confidence intervals (CI) for the association between anti-EBV antibody level and EBV-positive classic Hodgkin 
lymphoma (cHL) vs. controls a 
EBV Protein and Array sequence  
Antibody 
Type 
t-test P 
EBV-positive 
cHL Mean 
Control 
Mean 
EBV-positive 
cHL Positivity 
Control 
Positivity 
OR tertile 2 
(95% CI) 
OR tertile 3 
(95% CI) 
P-trend 
BBRF1 (Late lytic) 
YP_001129476.1-102746-104587 
IgG 1.4×10-7 1.34 1.09 68.3% 47.5% 1.33 (0.69, 2.54) 2.66 (1.45, 4.90) 1.0×10-3 
BcLF1 (VCA_p160) 
AFY97965.1-125044-120899-1 
IgG 1.8×10-7 1.27 1.04 63.3% 41.8% 1.73 (0.88, 3.41) 3.94 (2.08, 7.45) 1.5×10-5 
Thymidine kinase (Early lytic) 
YP_001129497.1-133399-131576 
IgG 5.1×10-7 1.51 1.28 90.6% 83.0% 0.96 (0.49, 1.85) 2.71 (1.50, 4.89) 3.8×10-4 
BBLF1 (Tegument protein) 
AFY97956.1-108555-108328 
IgG 1.2×10-6 2.09 1.83 98.6% 90.1% 1.67 (0.84, 3.32) 3.68 (1.95, 6.96) 3.2×10-5 
BBLF1 (Tegument protein) 
YP_001129480.1-109516-109289 
IgA 4.6×10-6 1.23 1.07 73.4% 51.8% 0.93 (0.47, 1.83) 3.03 (1.67, 5.47) 5.8×10-5 
BBLF1 (Tegument protein) 
YP_001129480.1-109516-109289 
IgG 4.6×10-6 2.21 1.96 99.3% 92.2% 2.23 (1.13, 4.40) 3.79 (1.98, 7.27) 5.7×10-5 
BBLF1 (Tegument protein) 
AFY97956.1-108555-108328 
IgA 6.6×10-6 1.23 1.07 76.3% 51.1% 1.37 (0.69, 2.72) 3.75 (2.02, 6.98) 7.0×10-6 
BcLF1 (VCA_p160) 
YP_001129493.1-126005-121860-1 
IgG 1.2×10-5 1.30 1.12 66.9% 53.9% 2.10 (1.09, 4.08) 3.27 (1.72, 6.20) 3.0×10-4 
BcLF1 (VCA_p160) 
CAA24794.1-137466-133321-1 
IgG 1.4×10-5 1.33 1.15 78.4% 60.3% 1.51 (0.80, 2.88) 2.50 (1.35, 4.62) 3.0×10-3 
BdRF1 (VCA_p40) 
AFY97974.1-136284-137321 
IgG 4.0×10-5 1.69 1.46 90.6% 83.0% 1.09 (0.56, 2.09) 2.54 (1.39, 4.63) 1.1×10-3 
BDLF3 (glycoprotein 150) 
AFY97964.1-118644-117940 
IgG 5.1×10-5 1.87 1.65 98.6% 91.5% 1.91 (1.00, 3.65) 2.82 (1.52, 5.24) 1.2×10-3 
BBRF3 (glycoprotein M) 
YP_001129479.1-107679-108896 
IgG 6.4×10-5 1.69 1.50 96.4% 85.8% 2.25 (1.19, 4.27) 2.56 (1.37, 4.78) 4.8×10-3 
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BDLF3 (glycoprotein 150) 
YP_001129490.1-119605-118901 
IgG 9.2×10-5 1.88 1.66 97.1% 87.9% 1.71 (0.89, 3.26) 2.80 (1.52, 5.18) 1.0×10-3 
BHRF1 (Bcl-2 homolog) 
YP_001129442.1-42204-42779 
IgG 1.1×10-4 1.43 1.29 91.4% 73.8% 2.87 (1.5, 5.48) 2.80 (1.46, 5.36) 4.2×10-3 
BFLF2 (Late lytic) 
YP_001129443.1-44763-43807 
IgG 1.1×10-4 1.10 0.99 50.4% 35.5% 1.74 (0.92, 3.29) 2.61 (1.41, 4.83) 2.6×10-3 
LMP-1 (Oncogene) 
YP_401722.1-168507-167702 
IgG 1.2×10-4 1.09 0.96 43.9% 19.9% 1.90 (1.01, 3.57) 4.99 (2.51, 9.94) 2.7×10-6 
BALF2 (EA(D)_p138) single-
stranded DNA binding protein 
YP_001129510.1-165796-162410-1 
IgG 1.3×10-4 1.26 1.13 74.8% 62.4% 1.48 (0.77, 2.83) 2.69 (1.45, 4.98) 1.3×10-3 
BARF1 (Oncogene) 
YP_001129453.1-66746-67654 
IgG 1.3×10-4 1.45 1.27 82.0% 74.5% 0.72 (0.38, 1.37) 1.79 (1.02, 3.16) 2.9×10-2 
VCA-p18 (synthetic peptide) IgG 0.0029 2.00 1.86 98.6% 92.9% 1.91 (1.02, 3.60) 2.50 (1.33, 4.71) 5.2×10-3 
EBNA1 (synthetic peptide) IgG 0.46 1.62 1.65 84.2% 87.9% 1.13 (0.64, 2.00) 0.67 (0.37, 1.22) 0.203 
EAd (synthetic peptide) IgG 0.05 0.97 0.92 10.8% 10.6% 1.49 (0.81, 2.74) 1.69 (0.92, 3.11) 0.101 
a Table is ordered by t-test p-value (lowest to highest).  ORs were adjusted for age group (<30, 30-39, 40-49, 50-59, and 60+ years), sex, and study area (UK, Denmark, and 
Sweden). The tertiles were calculated using the underlying antibody distribution among controls.  All odds ratios are expressed relative to the referent group of tertile 1 (lowest 
third of antibody distribution).  Three synthetic peptides printed in the array were shown for comparison.  
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Table 3. Odds ratios (OR) and 95% confidence intervals (CI) for the association between anti-EBV antibody level and EBV-positive classic Hodgkin lymphoma (cHL) vs. 
EBV-negative cHLa 
EBV Protein and Array 
sequence  
Antibody 
Type 
t-test P 
EBV-positive 
cHL Mean 
EBV-negative 
cHL Mean 
EBV-positive 
cHL Positivity 
EBV-negative 
cHL Positivity 
OR tertile 2 
(95% CI) 
OR tertile 3 
(95% CI) 
P-trend 
BBRF1 (Late lytic) 
YP_001129476.1-102746-
104587 
IgG 7.6×10-6 1.34 1.08 68.3% 51.4% 1.54 (0.69, 3.43) 2.94 (1.32, 6.52) 7.2×10-3 
BZLF1 (Zta) 
CAA24861.1-102338-102210 
IgG 1.4×10-5 1.79 1.51 97.1% 90.0% 2.53 (1.17, 5.48) 4.94 (2.13, 11.5) 2.1×10-4 
BARF1 (Oncogene) 
YP_001129453.1-166746-
167654 
IgG 1.9×10-5 1.45 1.20 82.0% 68.6% 1.09 (0.51, 2.35) 3.29 (1.58, 6.83) 1.4×10-3 
BdRF1 (VCA_p40) 
AFY97974.1-136284-137321 
IgG 3.5×10-5 1.69 1.40 90.6% 74.3% 1.50 (0.67, 3.39) 4.16 (1.89, 9.14) 2.5×10-4 
BVRF2 (viral capsid) 
YP_001129501.1-136465-
138282 redesigned 
IgG 1.0×10-4 1.02 0.91 43.2% 24.3% 2.54 (1.16, 5.57) 5.27 (2.15, 12.9) 3.1×10-4 
BKRF4 (Late lytic) 
YP_001129474.1-99676-100329 
IgG 1.1×10-4 1.14 0.99 49.6% 25.7% 1.50 (0.68, 3.33) 3.36 (1.58, 7.14) 1.6×10-3 
VCA-p18 (synthetic peptide) IgG 0.0028 2.00 1.83 98.6% 88.6% 1.84 (0.84, 4.03) 2.90 (1.25, 6.68) 0.013 
EBNA1 (synthetic peptide) IgG 0.57 1.62. 1.65 84.2% 85.7% 0.72 (0.35, 1.47) 0.74 (0.33, 1.64) 0.44 
EAd (synthetic peptide) IgG 0.09 0.97 0.91 10.8% 11.4% 2.29 (1.03, 5.08) 1.51 (0.71, 3.22) 0.33 
a Table is ordered by t-test p-value (lowest to highest).  ORs were adjusted for age group (<30, 30-39, 40-49, 50-59, and 60+ years), sex, and study area (UK, Denmark, and Sweden). 
The tertiles were calculated using the underlying antibody distribution among controls.  All odds ratios are expressed relative to the referent group of tertile 1 (lowest third of antibody 
distribution).  Three synthetic peptides printed in the array were shown for comparison. 
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Figure legends 
Figure 1. Case-control differences in the mean antibody response for EBV-positive cHL cases vs. 
controls.  A) Association between anti-EBV antibodies against proteins from different EBV life cycles 
and EBV-positive cHL (red, IgA; blue, IgG). The dashed line represents the statistically significant P 
value threshold after Bonferroni correction. P values were obtained from SKAT-C tests.  B) The x-axis 
displays the fold change (case vs. control ratio of standardized signal intensity) for all antibodies with 
CV<20%. The y-axis illustrates the P value corresponding to the t-test for a difference in SI between 
cases and controls. Sixteen IgG antibodies and two IgA antibodies were significantly elevated in EBV-
positive cHL cases compared to controls at the P≤0.00013 (Bonferroni P ≤0.05) threshold.  The four 
antibodies with the smallest P values are highlighted.  
Figure 2.  Case-control differences in the mean antibody response for EBV-negative cHL cases vs. 
controls.  A) Association between anti-EBV antibodies against proteins from different EBV life cycles 
and EBV-negative cHL (red, IgA; blue, IgG). The dashed line represents the statistically significant P 
value threshold after Bonferroni correction. P values were obtained from SKAT-C tests.  B) The x-axis 
displays the fold change (case vs. control ratio of standardized signal intensity) for all antibodies with 
CV<20%. The y-axis illustrates the P value corresponding to the t-test for a difference in standardized 
signal intensity between cases and controls.  No anti-EBV antibodies were significantly elevated in EBV-
negative cHL cases compared to controls 
Figure 3.  Case-case comparison.  A) Case-case differences in standardized signal intensity (SSI) for 
cases with EBV-positive cHL vs. EBV-negative cHL. The x-axis displays the fold change (ratio of SSI) 
for all antibodies with CV<20%. The y-axis illustrates the P value corresponding to the t-test for a 
difference in SI between EBV-positive vs. EBV-negative cHL. A total of six IgG antibodies were 
significantly elevated in EBV-positive vs. EBV-negative cHL at the P≤0.00013 (Bonferroni P ≤0.05) 
threshold. The four antibodies with the smallest P values are highlighted.  B) Receiver operating curve 
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(ROC) for classifying cHL tumors as either EBV positive or negative using the two selected serological 
markers BZLF1-IgG and BdRF-IgG.  Dotted line: patient demographics (age, sex, and residential area) 
alone.  Solid line: a combination of BZLF1-IgG and BdRF-IgG and patient demographics.  
Figure S1.  Average standardized signal intensity for the four anti-EBV IgG antibodies with the 
lowest P values for the comparison between EBV-positive cHL cases and controls.  A) BBRF1; B) 
BcLF1; C) Thymidine Kinase; D) BBLF1.  The dashed line represents the cutoff for positivity.  P values 
from the global ANOVA test and each two-way t-test (e.g., EBV-positive cHL vs. EBV-negative cHL) 
are listed. Boxes show interquartile range (IQR). 
Figure S2.  Correlation between BBRF-IgG and the A) number of circulating B-cells infected with 
EBV and B) chemokine CCL17 (thymus and activation-regulated chemokine TARC) levels.  The x-
axis displays the antibody levels of BBRF-IgG.  The y-axis is presented in logarithmic scale.  The 
regression line is based on linear regression and the 95% confidence interval (shadows) is illustrated.  
Correlation (cor) and P value are obtained from Spearman correlation. 
Figure S3. Average standardized signal intensity for the two anti-EBV IgG antibodies selected to 
distinguish EBV tumor status.  A) BZLF1 and B) BdRF1. The dashed line represents the cutoff for 
positivity.  P values from the global ANOVA test and each two-way t-test are listed.  
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Supplementary Materials 
 We developed an EBV protein microarray targeting IgG and IgA antibodies against 199 predicted 
EBV protein sequences representing non-redundant open reading frames (86 EBV proteins) from five 
prototypical EBV strains (AG876, Akata, B95-8, Mutu, and Raji).  Each of the protein sequences was 
cloned into the pXT7 expression vector, expressed using the E. coli cell-free protein system, and printed 
onto the microarray.  Sequences included N-terminal 10x histidine (His) and C-terminal hemagglutinin 
(HA) tags to confirm expression on the microarray.  High coverage was achieved across the five 
prototypical EBV strains and ten Chinese strains, with >97% of the predicted sequences from each strain 
represented on the microarray at >99% homology.  We also included three synthetic EBV peptides that 
are putative cancer biomarkers (VCAp18, EBNA1, and early antigen [EA] p47), bringing the total 
number of anti-EBV probes on the array to 202. 
After testing, raw signal intensities were corrected for spot-specific background using the Axon 
GenePix Pro 7 software and were variant log-transformed using variance stabilizing normalization  
transformation in Gmine (http://cgenome.net/wiki/index.php/Genomics_Data_Miner).  In addition to the 
202 EBV sequences, we included four “no DNA” (no translated protein) spots to assess person-specific 
background (e.g., E.coli reactivity).  We defined a lower limit of detection corresponding to the upper 
bound of the lowest quartile (Q1) of this “no DNA control” distribution and assigned that level to all 
spots that fell into Q1.  To remove potential differences in this background between cases and controls,, 
the array output for each participant was divided by the person-specific background (mean +1.5 standard 
deviations of four “no DNA” spots) prior to analysis, referred to as the standardized signal intensity (SSI).  
Positivity was defined as a SSI >1.0, and the SSI for each marker was further grouped into three 
categories, with cutoffs for the categories defined using tertiles of the distribution of a given marker 
among the 141 controls. 
 
30 
Table S1. Array Description 
Spot.ID Marker Life_cycle 
synthetic antigen VCA_p18 Late lytic 
synthetic antigen EBNA1 Latent 
synthetic antigen EAD_p47 Early lytic 
YP_001129436.1-1026-1196 LMP2A Latent 
YP_001129465.1-86654-87013 EBNA3C Latent 
YP_001129474.1-99676-100329 BKRF4 Late lytic 
YP_001129477.1-104490-105326 BBRF2 Late lytic 
YP_001129485.1-117754-118890 BGRF1/BDRF1 Late lytic 
YP_001129470.1-94844-96457 BRRF2 Late lytic 
YP_001129467.1-90855-90724 BZLF1 (ZEBRA) 
Immediate early 
lytic 
YP_001129464.1-83074-83430 EBNA3B Latent 
YP_001129507.1-157772-154725-2 BALF5 (EARLY GENE; DNA POL) Early lytic 
YP_001129459.1-76320-75484 DUTPASE Early lytic 
YP_001129451.1-63084-64178 CAPSID Late lytic 
YP_001129444.1-46353-44776 BFLF1 Late lytic 
YP_001129494.1-126004-128256 HYPOTHETICAL Early lytic 
YP_001129463.1-80447-82888 EBNA3A Latent 
YP_001129440.1-20824-20955 EBNA-LP Latent 
YP_001129436.1-167587-167942 LMP2A Latent 
YP_001129464.1-83509-86532-2 EBNA3B Latent 
YP_001129500.1-136454-135636 BVLF1 Late lytic 
YP_001129455.1-68964-70037 BMRF2 Glycoprotein 
YP_001129438.1-1736-5692-2 FGAM Other/Unknown 
YP_001129496.1-131574-129454 BXLF2 (GP85/GH) Glycoprotein 
YP_001129467.1-91045-90941 BZLF1 (ZEBRA) 
Immediate early 
lytic 
YP_001129463.1-80026-80361 EBNA3A Latent 
YP_001129478.1-105928-105323 BBLF2/3 Early lytic 
YP_001129473.1-98895-99662 GLYCOSYLASE Other/Unknown 
YP_001129446.1-46719-47729 BFRF1 (UL34 homolog) Late lytic 
YP_001129481.1-110883-109471 BGLF5 (EARLY GENE; ALK EXO) Early lytic 
YP_001129509.1-162392-160335 BALF3 Late lytic 
YP_001129507.1-157772-154725-1 BALF5 (EARLY GENE; DNA POL) Early lytic 
YP_001129440.1-35558-35662 EBNA-LP Latent 
YP_001129460.1-76393-76701 BLRF1 Late lytic 
YP_001129442.1-42204-42779 BHRF1 (BCL2 ANALOGUE) Early lytic 
YP_001129515.1-169948-169188 LMP1 Latent 
YP_001129486.1-115415-114405 BGLF2 Early lytic 
YP_001129505.1-153178-151769 LF1 Other/Unknown 
YP_001129493.1-126005-121860-1 
BCLF1 (MAJOR CAPSID 
PROTEIN) Late lytic 
YP_001129436.1-1574-1680 LMP2A Latent 
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YP_001129515.1-170457-170190 LMP1 Latent 
YP_001129448.1-49335-49865 BFRF3 Late lytic 
YP_001129503.1-139063-138317 BILF2 (GP55-78) Glycoprotein 
YP_001129484.1-113481-112483 BGLF3 Late lytic 
YP_001129456.1-71967-70589 BSLF2/BMLF1 
Immediate early 
lytic 
YP_001129476.1-102746-104587 BBRF1 Late lytic 
YP_001129436.1-360-458 LMP2A Latent 
YP_001129436.1-540-788 LMP2A Latent 
YP_001129439.1-9659-10171 BCRF1 Late lytic 
YP_001129498.1-133398-134144 BXRF1 Late lytic 
YP_001129510.1-165796-162410-2 DNA BINDING Early lytic 
YP_001129497.1-133399-131576 THY.KINASE Early lytic 
YP_001129449.1-59370-49906-3 BPFL1 Late lytic 
YP_001129515.1-170111-170025 LMP1 Latent 
YP_001129489.1-117772-117539 BDLF3 (GP100-150) Glycoprotein 
YP_001129467.1-91697-91197 BZLF1 (ZEBRA) 
Immediate early 
lytic 
YP_001129490.1-119605-118901 BDLF3 (GP100-150) Glycoprotein 
YP_001129443.1-44763-43807 BFLF2 Late lytic 
YP_001129468.1-93725-91908 BRLF1 (IMMEDIATE EARLY) 
Immediate early 
lytic 
YP_001129449.1-59370-49906-2 BPFL1 Late lytic 
YP_001129436.1-871-951 LMP2A Latent 
YP_001129480.1-109516-109289 BBLF1 Early lytic 
YP_001129461.1-76771-77259 BLRF2 Late lytic 
YP_001129488.1-117560-116883 BDLF4 Early lytic 
YP_001129506.1-154125-153187 BILF1 Glycoprotein 
YP_001129504.1-151808-150519 HYPOTHETICAL Early lytic 
YP_001129501.1-136465-138282 BVRF2 (VCAP40) Late lytic 
YP_001129440.1-29887-29952 EBNA-LP Latent 
YP_001129436.1-1280-1495 LMP2A Latent 
YP_001129483.1-112496-112035 BGLF3 Late lytic 
YP_001129466.1-90630-89959 BZLF2 (GP42) Glycoprotein 
YP_001129469.1-93724-94656 BRRF1 
Immediate early 
lytic 
YP_001129491.1-120928-119666 BDLF2 Glycoprotein 
YP_001129464.1-83509-86532-1 EBNA3B Latent 
YP_001129440.1-35441-35473 EBNA-LP Latent 
YP_001129436.1-58-272 LMP2A Latent 
YP_001129472.1-98500-98913 BKRF2 (GP25/GL) Glycoprotein 
YP_001129512.1-166530-167195 BARF1 Early lytic 
YP_001129453.1-166746-167654 BARF1 Early lytic 
YP_001129479.1-107679-108896 BBRF3 Glycoprotein 
YP_001129493.1-126005-121860-2 
BCLF1 (MAJOR CAPSID 
PROTEIN) Late lytic 
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YP_001129438.1-1736-5692-1 FGAM Other/Unknown 
YP_001129445.1-46352-46759 BFRF1A Other/Unknown 
YP_001129458.1-74770-75426 BSRF1 Late lytic 
YP_001129492.1-121844-120939 CAPSID Late lytic 
YP_001129454.1-67745-68959 BMRF1 (EAD) Early lytic 
YP_001129499.1-133954-135666 BVRF1 Late lytic 
YP_001129510.1-165796-162410-1 DNA BINDING Early lytic 
AFY97829.1-82733-83089 EBNA3B Latent 
AFY97840.1-62772-59044-2 BOLF1 Late lytic 
CAA24859.1-98371-98730 EBNA3C Latent 
CAA24827.1-122341-120929 BGLF5 (EARLY GENE; ALK EXO) Early lytic 
AFY97909.1-540-788 LMP2A Latent 
AFY97894.1-154809-155094 RPMS1 Latent 
CAA24811.1-167303-166998 BNLF2B Early lytic 
CAA24828.1-123692-122328 BGLF4 Early lytic 
CAA24858.1-95788-98247 EBNA3B Latent 
AFY97958.1-116811-116578 BDLF3 (GP100-150) Glycoprotein 
AFY97916.1-36198-37658 EBNA2 Latent 
AFY97906.1-168513-168246 LMP1 Latent 
AFY97882.1-118329-117625 BDLF3 (GP100-150) Glycoprotein 
AFY97841.1-59051-49692-1 BPFL1 Late lytic 
CAB56339.1-48385-48552 UNCHARACTERIZED Other/Unknown 
CAA24796.1-139642-140916 BTRF1 Late lytic 
CAA24805.1-156746-153699-1 BALF5 (EARLY GENE; DNA POL) Early lytic 
AFY97956.1-108555-108328 BBLF1 Early lytic 
AFY97955.1-109922-108510 BGLF5 (EARLY GENE; ALK EXO) Early lytic 
AFY97832.1-35494-35598 EBNA-LP Latent 
AFY97877.1-116284-115607 BDLF4 Early lytic 
CAA24861.1-102338-102210 BZLF1 (ZEBRA) 
Immediate early 
lytic 
CAA24873.1-40189-41340 BWRF1  Other/Unknown 
CAA24794.1-137466-133321-1 
BCLF1 (MAJOR CAPSID 
PROTEIN) Late lytic 
AFY97910.1-59-272 LMP2B Latent 
AFY97929.1-67486-68700 BMRF1 (EAD) Early lytic 
AFY97906.1-168167-168081 LMP1 Latent 
AFY97901.1-160450-158393 BALF3 Late lytic 
CAB56340.1-84288-84169 BSLF2/BMLF1 
Immediate early 
lytic 
CAA24829.1-124938-125915 BGRF1/BDRF1 Late lytic 
CAA24839.1-71527-62078-3 BPFL1 Late lytic 
AFY97988.1-166888-166706 BNLF2A Late lytic 
AFY97987.1-168367-167562 LMP1 Latent 
AFY97832.1-35377-35409 EBNA-LP Latent 
AFY97842.1-95349-97142 EBNA1 Latent 
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CAA24861.1-102530-102423 BZIP 
Immediate early 
lytic 
CAA24798.1-144860-145606 BXRF1 Late lytic 
CAA24839.1-71527-62078-2 BPFL1 Late lytic 
AFY97910.1-1026-1196 LMP2B Latent 
AFY97946.1-98716-99369 BKRF4 Late lytic 
AFY97868.1-104653-104048 BBLF2/3 Early lytic 
AFY97838.1-47422-49197 BFRF2 Late lytic 
CAB56341.1-92663-92767 BLRF3 Late lytic 
CAA24860.1-102116-101445 BZLF2 (GP42) Glycoprotein 
AFY97941.1-90112-90008 BZLF1 (ZEBRA) 
Immediate early 
lytic 
AFY97980.1-156149-153102-2 BALF5 (EARLY GENE; DNA POL) Early lytic 
AFY97883.1-124729-120584-2 
BCLF1 (MAJOR CAPSID 
PROTEIN) Late lytic 
AFY97856.1-86125-88794 EBNA3C Latent 
CAA24810.1-165517-164855 BALF1 Early lytic 
CAA24807.1-161678-159312 BALF3 Late lytic 
AFY97917.1-35572-35676 EBNA-LP Latent 
AFY97950.1-104968-104363 BBLF2/3 Early lytic 
YP_001129457.1-74727-72103 BSLF1 (EARLY GENE) Early lytic 
AFY97861.1-93701-95314 BBRF2 Late lytic 
CAA24838.1-61507-62037 BFRF3 Late lytic 
AFY97981.1-159642-159726 A73 Other/Unknown 
AFY97924.1-49199-49729 BFRF3 Late lytic 
AFY97830.1-80050-82545 EBNA3A Latent 
CAA24861.1-103155-102655 BZLF1 (ZEBRA) 
Immediate early 
lytic 
CAA24824.1-119080-117515 BBLF2 Early lytic 
AFY97981.1-156513-156598 A73 Other/Unknown 
AFY97909.1-165963-166318 LMP2A Latent 
YP_001129452.1-64253-66733 
BORF2 (EARLY GENE; RIBO 
UNIT) Early lytic 
AFY97836.1-46138-46545 BRFR1A Early lytic 
CAA24817.1-109958-110371 BKRF2 (GP25/GL) Glycoprotein 
CAA24832.1-128374-126851 BGLF1 Late lytic 
AFY97917.1-35455-35487 EBNA-LP Latent 
AFY97989.1-166696-166400 BNLF2B Early lytic 
AFY97856.1-85691-86050 EBNA3C Latent 
AFY97897.1-151239-149830 LF1 Other/Unknown 
AFY97883.1-124729-120584-1 
BCLF1 (MAJOR CAPSID 
PROTEIN) Late lytic 
CAA24856.1-92243-92602 EBNA3A Latent 
AFY97976.1-155128-155413 RPMS1 Latent 
YP_401636.1-20698-20763 EBNA-LP Latent 
YP_401707.1-143344-140570 LF3 Other/Unknown 
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AFY97915.1-80252-82747 EBNA3A Latent 
YP_001129475.1-102801-100372 
redesigned BBLF4 (EARLY GENE) Early lytic 
YP_001129441.1-36201-37565 redesigned EBNA2 Latent 
CAA24816.1-107950-109875 redesigned EBNA1 Latent 
AFY97965.1-125044-120899-1 
BCLF1 (MAJOR CAPSID 
PROTEIN) Late lytic 
YP_401715.1-160908-158851 BALF3 Late lytic 
CAA24858.1-95353-95709 EBNA3B Latent 
CAA24839.1-71527-62078-4 BPFL1 Late lytic 
AFY97987.1-168876-168609 LMP1 Latent 
CAA24877.1-48504-49967 redesigned EBNA2 Latent 
AFY97966.1-125043-127295 HYPOTHETICAL Early lytic 
YP_401645.1-40269-38287 BHLF1 Early lytic 
AFY97990.1-85953-86312 EBNA3C Latent 
YP_001129449.1-59370-49906-1 
redesigned BPFL1 Late lytic 
AFY97974.1-136284-137321 BDRF1 Late lytic 
AFY97964.1-118644-117940 BDLF3 (GP100-150) Glycoprotein 
CAA24806.1-159322-156749 BALF4 (GP110/GB) Glycoprotein 
AFY97913.1-95532-97457 EBNA1 Latent 
YP_401722.1-168507-167702 LMP1 Latent 
AFY97978.1-151556-150147 LF1 Other/Unknown 
YP_001129449.1-59370-49906-4 
redesigned BPFL1 Late lytic 
CAA24854.1-92153-89430 redesigned BLLF1 (GP350) Glycoprotein 
AFY97959.1-116599-115922 BDLF4 Early lytic 
YP_001129465.1-87088-89937 redesigned EBNA3C Latent 
YP_401669.1-80382-82877 EBNA3A Latent 
AFY97943.1-93884-95497 BRRF2 Late lytic 
YP_401636.1-35590-35694 EBNA-LP Latent 
YP_401722.1-168670-168584 LMP1 Latent 
YP_001129501.1-136465-138282 
redesigned BVRF2 (VCAP40) Late lytic 
CAA24859.1-98805-101423 redesigned EBNA3C Latent 
AFY97921.1-46216-46623 BFRF1A Other/Unknown 
YP_001129462.1-79936-77276 redesigned BLLF1 (GP350) Glycoprotein 
CAA24821.1-114259-111830 BBLF4 (EARLY GENE) Early lytic 
YP_401722.1-168670-168584 LMP1 Latent 
YP_001129447.1-47636-49411 redesigned BFRF2 Late lytic 
CAA24839.1-71527-62078-1 redesigned BPFL1 Late lytic 
CAA24880.1-59808-61583 NA 
Immediate early 
lytic 
YP_001129508.1-160348-157775 
redesigned BALF4 (GP110/GB) Glycoprotein 
CAA24841.1-75239-71520-1 BOLF1 Late lytic 
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Table S2. Odds ratio and 95% confidence interval for the association between EBNA-1:EBNA-2 ratio ≤1 vs. >1 and 
classic Hodgkin lymphoma (cHL) * 
EBNA1 EBNA2 
EBV-negative cases vs. controls   EBV-positive cases vs. controls 
OR (95% CI) P value  OR (95% CI) P value 
Synthetic peptide AFY97916.1-36198-37658 1.45 (0.60, 3.51) 0.409   1.63 (0.81, 3.29) 0.169 
Synthetic peptide YP_001129441.1-36201-37565 1.03 (0.55, 1.94) 0.927  1.22 (0.74, 2.01) 0.433 
Synthetic peptide CAA24877.1-48504-49967 1.67 (0.67, 4.11) 0.269  1.81 (0.87, 3.77) 0.110 
CAA24816.1-107950-109875 AFY97916.1-36198-37658 1.18 (0.62, 2.24) 0.611  1.09 (0.65, 1.83) 0.738 
CAA24816.1-107950-109875 YP_001129441.1-36201-37565 0.81 (0.45, 1.47) 0.489  1.59 (0.97, 2.62) 0.068 
CAA24816.1-107950-109875 CAA24877.1-48504-49967 1.63 (0.71, 3.70) 0.247  1.81 (0.94, 3.49) 0.077 
AFY97913.1-95532-97457 AFY97916.1-36198-37658 0.98 (0.31, 3.06) 0.973  2.30 (0.77, 6.87) 0.136 
AFY97842.1-95349-97142 YP_001129441.1-36201-37565 0.95 (0.30, 3.03) 0.929  3.42 (0.92, 12.7) 0.067 
AFY97842.1-95349-97142 CAA24877.1-48504-49967 1.03 (0.48, 2.21) 0.933  1.95 (0.98, 3.88) 0.056 
AFY97913.1-95532-97457 AFY97916.1-36198-37658 0.46 (0.17, 1.22) 0.119  0.34 (0.15, 0.77) 0.010 
AFY97913.1-95532-97457 YP_001129441.1-36201-37565 0.65 (0.14, 3.10) 0.588  0.37 (0.11, 1.22) 0.103 
AFY97913.1-95532-97457 CAA24877.1-48504-49967 0.40 (0.20, 0.82) 0.012  0.42 (0.23, 0.77) 0.005 
* ORs were adjusted for age group (<30, 30-39, 40-49, 50-59, and 60+ years), sex, and study area (UK, Denmark, and Sweden) 
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Table S3. Odds ratios (OR) and 95% confidence intervals (CI) for the association between anti-EBV 
antibody level and EBV-positive classic Hodgkin lymphoma (cHL) vs. controls among participants from the 
Scandinavian Lymphoma Etiology study, additionally adjusted for a history of infectious mononucleosis. * 
EBV Protein and Array sequence  
Antibody 
Type 
OR tertile 2 
(95% CI) 
OR tertile 3 
(95% CI) 
P-trend 
BBRF1 (Late lytic) 
YP_001129476.1-102746-104587 
IgG 1.58 (0.44, 5.63) 2.01 (0.55, 7.32) 0.292 
BcLF1 (VCA_p160) 
AFY97965.1-125044-120899-1 
IgG 1.17 (0.27, 5.03) 4.50 (1.18, 17.2) 0.016 
Thymidine kinase (Early lytic) 
YP_001129497.1-133399-131576 
IgG 0.64 (0.15, 2.70) 2.96 (0.85, 10.4) 0.044 
BBLF1 (Tegument protein) 
AFY97956.1-108555-108328 
IgG 1.61 (0.37, 6.94) 4.87 (1.17, 20.2) 0.014 
BBLF1 (Tegument protein) 
YP_001129480.1-109516-109289 
IgA 0.98 (0.28, 3.52) 2.51 (0.77, 8.18) 0.114 
BBLF1 (Tegument protein) 
YP_001129480.1-109516-109289 
IgG 2.10 (0.50, 8.88) 5.05 (1.24, 20.5) 0.016 
BBLF1 (Tegument protein) 
AFY97956.1-108555-108328 
IgA 1.37 (0.36, 5.21) 3.30 (0.99, 11.0) 0.042 
BcLF1 (VCA_p160) 
YP_001129493.1-126005-121860-1 
IgG 1.87 (0.49, 7.13) 2.44 (0.64, 9.23) 0.201 
BcLF1 (VCA_p160) 
CAA24794.1-137466-133321-1 
IgG 3.09 (0.73, 13.1) 4.48 (1.03, 19.4) 0.052 
BdRF1 (VCA_p40) 
AFY97974.1-136284-137321 
IgG 0.76 (0.19, 3.03) 4.41 (1.20, 16.2) 0.008 
BDLF3 (glycoprotein 150) 
AFY97964.1-118644-117940 
IgG 0.74 (0.19, 2.82) 3.42 (0.94, 12.4) 0.038 
BBRF3 (glycoprotein M) 
YP_001129479.1-107679-108896 
IgG 1.05 (0.29, 3.84) 1.51 (0.42, 5.39) 0.480 
BDLF3 (glycoprotein 150) 
YP_001129490.1-119605-118901 
IgG 1.82 (0.42, 7.95) 8.91 (2.04, 39.0) 0.001 
BHRF1 (Bcl-2 homolog) 
YP_001129442.1-42204-42779 
IgG 3.03 (0.73, 12.5) 2.87 (0.70, 11.7) 0.207 
BFLF2 (Late lytic) 
YP_001129443.1-44763-43807 
IgG 1.27 (0.33, 4.88) 8.52 (2.12, 34.2) 0.001 
LMP-1 (Oncogene) 
YP_401722.1-168507-167702 
IgG 2.84 (0.68, 11.9) 4.74 (1.13, 19.9) 0.035 
BALF2 (EA(D)_p138) single-
stranded DNA binding protein 
YP_001129510.1-165796-162410-1 
IgG 1.55 (0.39, 6.24) 2.75 (0.77, 9.81) 0.111 
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BARF1 (Oncogene) 
YP_001129453.1-166746-167654 
IgG 0.62 (0.17, 2.27) 2.72 (0.81, 9.06) 0.080 
* Table is ordered by t-test p-value (lowest to highest) from the Table 2.  ORs were adjusted for age group (<30, 
30-39, 40-49, 50-59, and 60+ years), sex, study area (Denmark and Sweden), and a history of infectious 
mononucleosis. The tertiles were calculated using the underlying antibody distribution among controls.  All odds 
ratios are expressed relative to the referent group of tertile 1 (lowest third of antibody distribution).   
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